Potential biomarkers in early arthritis include differential infiltration by CD22+ve B cells and CD38+ plasma cells in patients with early arthritis differentiating RA vs. non RA inflammatory arthritis (40). This evidence concerns the gene CD38 and rheumatoid arthritis.